Abstract Library

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#3472 Reduction of 64Cu-DOTATATE activity dose for somatostatin receptor PET imaging of patients with neuroendocrine neoplasms

Introduction: Frequent somatostatin receptor (SSR) PET imaging is key in the clinical management of patients with neuroendocrine neoplasms (NEN) and measures to reduce the radiation exposure should be pursued.

Conference:

Presenting Author:

Authors: Loft M, Carlsen E, Johnbeck C, Jensen C, Andersen F,

Keywords: 64Cu-DOTATATE, neuroendocrine neoplasm, PET imaging, SSR imaging,

#3443 Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy

Introduction: Non-invasive tools to improve prognostication are warranted in patients with neuroendocrine neoplasms (NEN). Expression of urokinase plasminogen activator receptor (uPAR) is present in many cancer types and associated with a poor outcome, but largely unknown in NEN. uPAR-targeted radionuclide therapy has proven effective in preclinical models and uPAR may be a potential target in NEN patients.

Conference:

Presenting Author: Carlsen E

Authors: Carlsen E, Loft M, Loft A, Berthelsen A, Langer S,

Keywords: urokinase plasminogen activator receptor (upar), neuroendocrine neoplasm, pet, prognosis, molecular imaging,

#3277 Single-institution experience with 18F-DOPA and 68Ga-DOTA-TOC as a PET imaging tracer for peptide receptor radionuclide therapy in well-differentiated neuroendocrine neoplasms

Introduction: In treatment of neuroendocrine neoplasms (NENs), confirmation of somatostatin receptor affinity with 68Ga-DOTA, is mandatory to determine eligibility for peptide receptor radionuclide therapy (PRRT). 18F-FDOPA tracer is also used in the diagnostic imaging of NENs, likely detecting additional lesions compared to 68Ga-DOTA.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Veenstra E, Noordzij W,

Keywords: neuroendocrine tumor, PET tracer, 18F-DOPA, 68Ga-DOTA-TOC, carbidopa, peptide receptor radionuclide therapy, PRRT,

#3103 Comparison of 18F-DOPA versus 68Ga-DOTA-TOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms

Introduction: 18F-DOPA and 68Ga-DOTA-TOC are two diagnostic PET tracers used in neuroendocrine neoplasms (NENs). As both tracers utilise different metabolic pathways, lesion detection results often show disparities, but comparative studies are lacking.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Veenstra E

Authors: Veenstra E, de Groot D, Brouwers A, Walenkamp A, Noordzij W,

Keywords: neuroendocrine tumor, PET, tracer, 18F-DOPA, 68GA-DOTA-TOC, tumor marker, carbidopa,